Analysts and calls -- US Bancorp Piper Jaffray Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Analysts and calls -- US Bancorp Piper Jaffray

Public Reply Prvt Reply Mark as Last Read File

Previous 10 PreviousNext

From: Icebrg	12/15/2004 2:32:34 PM
	of 22

Two Biotechnology Picks For 2005 12.15.04, 1:37 PM ET Piper Jaffray said CV Therapeutics (nasdaq: CVTX - news - people ) and Incyte (nasdaq: INCY - news - people ) are two of its top picks for 2005 in biotechnology. For CV Therapeutics, Piper Jaffray cited "positive clinical and regulatory developments for Ranexa," a chronic angina treatment. The research firm said Incyte's Reverset could be the next breakthrough drug for HIV. Elsewhere in coverage, Piper Jaffray said five biotechs that will see catalysts in the next four to six weeks include CoTherix (nasdaq: CTRX - news - people ), Gen-Probe (nasdaq: GPRO - news - people ), Millennium Pharmaceuticals (nasdaq: MLNM - news - people ), MannKind (nasdaq: MNKD - news - people ) and Neurocrine Biosciences (nasdaq: NBIX - news - people ). CoTherix has filed for approval for Ventavis, an aerosolized prostacyclin to treat pulmonary hypertension; the application was granted priority review, establishing a Food and Drug Administration action date of Dec. 31. "Ventavis has a favorable risk-benefit profile and should warrant FDA approval," Piper Jaffray said. Gen-Probe could see upside from three catalysts: the outcome of an arbitration with Bayer (nyse: BAY - news - people ), in which Gen-Pro hopes to reclaim rights to its HIV and hepatitis C assays for clinical diagnostics applications; an announcement on Gen-Pro's strategy to enter the human papillomavirus testing market; and the outcome of an evaluation by Quest Diagnostics (nyse: DGX - news - people ) of Gen-Pro's Tigris machine for chlamydia-gonorrhea testing. Millennium Pharmaceuticals will detail its future development plans for Velcade in lung cancer by mid-January. Piper Jaffray continues to expect positive data from a 120-patient, Phase IIb study of Mannkind's Technosphere Insulin. Wednesday is the FDA action date for Estorra from Sepracor (nasdaq: SEPR - news - people ). Estorra is an insomnia agent that competes with Neurocrine's indiplon; expectations are already high for a clean label for Estorra, so any shortcoming from a close reading of the label may be a near-term positive for Neurocrine.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 PreviousNext